Alnylam Pharmaceuticals | ALNY - Net Income


Alnylam Pharmaceuticals reported $164.49M in Net Income for its fiscal quarter ending in June of 2026.





Net Income Change Date
Acadia Pharmaceuticals USD 31.5M 27.86M Jun/2026
Agios Pharmaceuticals USD -99.11M 8.93M Mar/2026
Alnylam Pharmaceuticals USD 164.49M 41.5M Jun/2026
Amgen USD 2.38B 556M Jun/2026
Arrowhead Research USD -132.73M 163.54M Mar/2026
BioCryst Pharmaceuticals USD 78.4M 167.45M Jun/2026
BioMarin Pharmaceutical USD 44.76M 60.76M Jun/2026
Incyte USD 585.6M 282.27M Jun/2026
Ionis Pharmaceuticals USD -114.65M 21.65M Jun/2026
Moderna USD -1.34B 517M Mar/2026
Neurocrine Biosciences USD 144.4M 53.5M Jun/2026
Novartis USD 3.16B 747M Mar/2026
PTC Therapeutics USD -2.81M 132.16M Mar/2026
Regeneron Pharmaceuticals USD 1.3B 569.7M Jun/2026
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Sanofi EUR 1.61B 2.42B Mar/2026
Sarepta Therapeutics USD 330.96M 743.18M Mar/2026
Takeda JPY 113.2B 137.52B Jun/2026
Tectonic Therapeutic USD -25.24M 6.02M Mar/2026
Ultragenyx Pharmaceutical USD -185M 56M Mar/2026
Vertex Pharmaceuticals USD 1.1B 68.4M Jun/2026
Xencor USD -21.73M 107.19M Jun/2026